Antibody response induced by the boost overdose during COVID-19 heterologous prime-boost vaccination strategy
| Autor: | Giuseppe Lippi, Francisco Sáez Raposo |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Vaccine overdose
COVID-19 Vaccines Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Clinical Biochemistry BAU Binding antibody units Heterologous CMIA chemiluminiscent microparticle immunoassay Antibodies Viral Biochemistry Article Immune system VORs Vaccine overdose recipients Humans Medicine T6 14 21 Time-points BNT162 Vaccine Ig G Immunoglobulin class G BNT162b2 vaccine biology business.industry Anti-SARS-CoV-2 RBD Ig G antibody SARS-CoV-2 Biochemistry (medical) Vaccination COVID-19 General Medicine Anti-SARS-CoV-2 RBD Ig G antibody Antibody response monitoring BNT162b2 vaccine COVID-19 SARS-CoV-2 Vaccination NHP Non-human primates Antibody response Immunization Antibody Formation Immunology RBD Receptor-binding domain biology.protein Antibody business Antibody response monitoring |
| Zdroj: | Digital.CSIC. Repositorio Institucional del CSIC instname Clinica Chimica Acta; International Journal of Clinical Chemistry |
| Popis: | 4 Paginas.-- 2 Tablas Background Measurement of anti-SARS-CoV-2 RBD Ig G antibody response is very important to define the dynamics of immunization in vaccine COVID-19 recipients. Materials and methods Sera from four BNT162b2 vaccine recipients who erroneously received vaccine overdose were analyzed at different time-points. Results At 6 days the serum increase of antibodies was analogous for the three SARS-CoV-2 naïve recipients. At 14 days the antibody level increased and reached a peak, though showing a different pattern among the three recipients. At 21 days the serum antibody level started to decrease from its maximum value. The data for the previously infected recipient were in agreement with values found in COVID-19 positive receivers. Thus, the prime-dose of vaccine was enough to elicit a significant antibody response. Conclusions In spite of the overdosage, this study confirms the efficiency of the BNT162b vaccine in eliciting a sustained antibody response as heterologous boost-vaccine in previously Oxford/AstraZeneca vaccinated recipients, as well as, prime-vaccine in COVID-19 infected receivers. Importantly, the humoral immune response of recipients was not proportional to the vaccine overdose. Nonetheless, we cannot portray a univocal effect of vaccine overdose concerning anti-SARS-CoV-2 antibody response because the values found were highly heterogeneous. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|